Overactive Bladder Market to Witness Growth by 2032, Estimates DelveInsight | Urovant Sciences, Bayer, Taiho Pharmaceutical, Astellas Pharma Inc, Kyorin Pharmaceutical, Novartis, Pfizer, GlaxoSmithKline

(New York, USA) DelveInsight's Overactive Bladder Market Insights report includes a comprehensive understanding of current treatment practices, overactive bladder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Discover which therapies are expected to grab the major overactive bladder market share @ https://www.delveinsight.com/report-store/overactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Overactive Bladder Market Report
• As per DelveInsight analysis, the overactive bladder market is expected to grow positively at a significant CAGR during the study period (2019-2032).
• Leading overactive bladder companies such as Urovant Sciences, Bayer, Taiho Pharmaceutical, Astellas Pharma Inc, Kyorin Pharmaceutical, Urovant Sciences, Novartis, Astellas Pharma US, Inc., Pfizer, GlaxoSmithKline, and others are developing novel overactive bladder drugs that can be available in the overactive bladder market in the coming years.
• Some of the key promising therapies for overactive bladder treatment include URO-902, BAY 1817080, TAC-302, Mirabegron, Vibegron, Darifenacin, Vesicare, SPM 907, Solabegron, Oxybutynin, and others.
• As per Partin et al. (2021), overactive bladder is common in men and women but tends to affect women disparately. Most epidemiologic studies report a prevalence of overactive bladder in women of approximately 1.5 to 2 times that of men and rates of UUI of 2 to 3 times those in men.

Overactive Bladder Overview
Overactive bladder (OAB) is a condition in which a person's need to urinate is so frequent that it negatively affects their life. Urination may be required frequently during the day, at night, or both. Urge incontinence occurs when there is a loss of bladder control. Incontinence affects more than 40% of people with overactive bladder. In contrast, overactive bladder causes 40% to 70% of urinary incontinence. The cause of overactive bladder is unknown. Obesity, caffeine, and constipation are risk factors. Diabetes, poor functional mobility, and chronic pelvic pain may exacerbate the overactive bladder symptoms.

Overactive bladder is characterized by four symptoms: urgency, urinary frequency, nocturia, and urge incontinence. The overactive bladder diagnosis is based primarily on the person's signs and symptoms and excludes other possible causes, such as infection. Urodynamics, a bladder scope, and ultrasound are generally unnecessary. Urine culture may also be performed to rule out infection.

Download the report to understand which factors are driving overactive bladder epidemiology trends @ https://www.delveinsight.com/sample-request/overactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Overactive Bladder Epidemiology Segmentation
The overactive bladder market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalent Cases
• Gender-specific Prevalent Cases
• Type-specific Prevalent Cases
• Diagnosed and Treatable Cases

Overactive Bladder Treatment Market
Overactive bladder is a group of symptoms that, while not fatal, can have a negative impact on quality of life. As a result, physicians must carefully balance the potential benefit of a specific overactive bladder treatment against the risk, severity, and reversibility of adverse effects. All patients with overactive bladder should receive behavioral therapies as first-line therapy (e.g., bladder training, bladder-control strategies, pelvic floor muscle training, fluid management). Antimuscarinic agents can be combined with behavioral strategies.

Oral antimuscarinics are second-line therapies for overactive bladder treatment (e.g., darifenacin [Enablex], fesoterodine [Toviaz], oxybutynin [Ditropan], solifenacin [Vesicare], tolterodine [Detrol], trospium[Sanctura]). When choosing between immediate-release and extended-release formulations, the extended-release formulation is preferred due to lower rates of dry mouth. Transdermal oxybutynin (gel [Gelnique] or patch [Oxytrol]) may also be available.

To know more about overactive bladder treatment, visit @ https://www.delveinsight.com/sample-request/overactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Overactive Bladder Therapies and Companies
• URO-902: Urovant Sciences
• BAY 1817080: Bayer
• TAC-302: Taiho Pharmaceutical
• Mirabegron: Astellas Pharma Inc
• Vibegron: Kyorin Pharmaceutical/Urovant Sciences
• Darifenacin: Novartis
• Vesicare: Astellas Pharma US, Inc.
• SPM 907: Pfizer
• Solabegron: GlaxoSmithKline
• Oxybutynin: Bayer

Learn more about the FDA-approved drugs for overactive bladder @ https://www.delveinsight.com/sample-request/overactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Overactive Bladder Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Overactive Bladder Companies: Urovant Sciences, Bayer, Taiho Pharmaceutical, Astellas Pharma Inc, Kyorin Pharmaceutical, Novartis, Pfizer, GlaxoSmithKline, and others
• Key Overactive Bladder Therapies: URO-902, BAY 1817080, TAC-302, Mirabegron, Vibegron, Darifenacin, Vesicare, SPM 907, Solabegron, Oxybutynin, and others
• Therapeutic Assessment: Overactive Bladder current marketed and emerging therapies
• Overactive Bladder Market Dynamics: Attribute Analysis of Emerging Overactive Bladder drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Overactive Bladder Market Access and Reimbursement

Discover more about overactive bladder drugs in development @ https://www.delveinsight.com/sample-request/overactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Overactive Bladder Market Key Insights
2. Overactive Bladder Market Report Introduction
3. Overactive Bladder Market Overview at a Glance
4. Overactive Bladder Market Executive Summary
5. Overactive Bladder Understanding and Overview
6. Overactive Bladder Treatment and Management
7. Overactive Bladder Epidemiology and Patient Population
8. Overactive Bladder Patient Journey
9. Overactive Bladder Marketed Drugs
10. Overactive Bladder Emerging Drugs
11. Seven Major Overactive Bladder Market Analysis
12. Overactive Bladder Market Outlook
13. Potential of Current and Emerging Therapies
14. Overactive Bladder KOL Views
15. Overactive Bladder Market Drivers
16. Overactive Bladder Market Barriers
17. Overactive Bladder Unmet Needs
18. SWOT Analysis
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

Trending Reports
• Familial Primary Pulmonary Hypertension Market : https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Astigmatism Market : https://www.delveinsight.com/report-store/astigmatism-market
• Neurostimulation Devices Market : https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Opioid Induced Constipation Market : https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Nonalcoholic Steatohepatitis Market : https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market
• Meningioma Market : https://www.delveinsight.com/report-store/meningioma-market
• Pediatric Growth Hormone Deficiency Pghd Market : https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
• Progressive Multifocal Leukoencephalopathy Market : https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Osteoarthritis Market : https://www.delveinsight.com/report-store/osteoarthritis-market
• Actinic Keratosis Market : https://www.delveinsight.com/report-store/actinic-keratosis-market
• Blood Gas And Electrolyte Analyzers Market : https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cerebral Aneurysm Market : https://www.delveinsight.com/report-store/cerebral-aneurysm-market
• Neurovascular Devices Market : https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Capnography Device Market : https://www.delveinsight.com/report-store/capnography-devices-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market

Contact Us:
Ankit Nigam
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.